WO2008084241A3 - Use of aminolevulinic acid and derivatives thereof - Google Patents

Use of aminolevulinic acid and derivatives thereof Download PDF

Info

Publication number
WO2008084241A3
WO2008084241A3 PCT/GB2008/000086 GB2008000086W WO2008084241A3 WO 2008084241 A3 WO2008084241 A3 WO 2008084241A3 GB 2008000086 W GB2008000086 W GB 2008000086W WO 2008084241 A3 WO2008084241 A3 WO 2008084241A3
Authority
WO
WIPO (PCT)
Prior art keywords
photosensitiser
pdt
composition
photoactivation
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/000086
Other languages
French (fr)
Other versions
WO2008084241A2 (en
Inventor
Hans Christian Wulf
Aslak Godal
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL08701770T priority Critical patent/PL2120921T3/en
Priority to SI200831500T priority patent/SI2120921T1/en
Priority to JP2009545231A priority patent/JP5814508B2/en
Priority to KR1020147014684A priority patent/KR20140076641A/en
Priority to US12/523,048 priority patent/US8759396B2/en
Priority to EP08701770.3A priority patent/EP2120921B1/en
Priority to ES08701770.3T priority patent/ES2546381T3/en
Priority to EP14163782.7A priority patent/EP2754439B1/en
Priority to DK08701770.3T priority patent/DK2120921T3/en
Application filed by Photocure ASA filed Critical Photocure ASA
Priority to CA2675334A priority patent/CA2675334C/en
Publication of WO2008084241A2 publication Critical patent/WO2008084241A2/en
Publication of WO2008084241A3 publication Critical patent/WO2008084241A3/en
Anticipated expiration legal-status Critical
Priority to US13/648,946 priority patent/US20130090592A1/en
Priority to US14/616,278 priority patent/US20150150972A1/en
Priority to US14/873,566 priority patent/US10543272B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides the use of a photosensitiser which is 5- aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10 % wt (e.g. 0.5 to 8 %wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side-effects of PDT are prevented or reduced by using (iii) or (iv) in combination with (i) and/or (ii).
PCT/GB2008/000086 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof Ceased WO2008084241A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DK08701770.3T DK2120921T3 (en) 2007-01-11 2008-01-11 The use of aminolevulinic acid, and derivatives thereof
JP2009545231A JP5814508B2 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and its derivatives
KR1020147014684A KR20140076641A (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof
US12/523,048 US8759396B2 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof
EP08701770.3A EP2120921B1 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof
ES08701770.3T ES2546381T3 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof
EP14163782.7A EP2754439B1 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid derivatives
PL08701770T PL2120921T3 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof
CA2675334A CA2675334C (en) 2007-01-11 2008-01-11 Reducing side effects associated with ala-based photodynamic therapy
SI200831500T SI2120921T1 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof
US13/648,946 US20130090592A1 (en) 2007-01-11 2012-10-10 Use of aminolevulinic acid and derivatives thereof
US14/616,278 US20150150972A1 (en) 2007-01-11 2015-02-06 Use of aminolevulinic acid and derivatives thereof
US14/873,566 US10543272B2 (en) 2007-01-11 2015-10-02 Use of aminolevulinic acid and derivatives thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0700580.4 2007-01-11
GBGB0700580.4A GB0700580D0 (en) 2007-01-11 2007-01-11 Use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/523,048 A-371-Of-International US8759396B2 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof
US13/648,946 Division US20130090592A1 (en) 2007-01-11 2012-10-10 Use of aminolevulinic acid and derivatives thereof

Publications (2)

Publication Number Publication Date
WO2008084241A2 WO2008084241A2 (en) 2008-07-17
WO2008084241A3 true WO2008084241A3 (en) 2008-09-18

Family

ID=37809842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000086 Ceased WO2008084241A2 (en) 2007-01-11 2008-01-11 Use of aminolevulinic acid and derivatives thereof

Country Status (13)

Country Link
US (4) US8759396B2 (en)
EP (3) EP2659888A1 (en)
JP (2) JP5814508B2 (en)
KR (2) KR20140076641A (en)
CN (3) CN104524576A (en)
CA (2) CA2675334C (en)
DK (1) DK2120921T3 (en)
ES (2) ES2546381T3 (en)
GB (1) GB0700580D0 (en)
PL (1) PL2120921T3 (en)
PT (1) PT2120921E (en)
SI (1) SI2120921T1 (en)
WO (1) WO2008084241A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2615870C2 (en) * 2011-12-19 2017-04-11 ФотоКьюэр АСА Emitter

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110224598A1 (en) * 2010-03-12 2011-09-15 Daniel Barolet Radiant near infrared light emitting diode exposure as skin preparation
GB0900461D0 (en) 2009-01-12 2009-02-11 Photocure Asa Photodynamic therapy device
WO2010142457A1 (en) * 2009-06-11 2010-12-16 Photocure Asa Semi-solid compositions and pharmaceutical products
JP2013521251A (en) * 2010-03-01 2013-06-10 フォトキュア エイエスエイ Beauty composition
JP6323978B2 (en) 2010-12-24 2018-05-16 アークレイ株式会社 Method for detecting cancer cells
CN102617378B (en) * 2011-01-26 2016-04-27 上海泺安医药技术有限公司 A kind of 2-(3 '-amino-2 '-oxygen-propyl group) malonic ester salt and preparation
KR101254758B1 (en) * 2011-02-28 2013-04-15 부산대학교병원 Synthesis of 5-aminolevulinic acid tetramer using ethylenediaminetetraacetic acid for photodynamic therapy
KR101254752B1 (en) * 2011-02-28 2013-04-15 부산대학교 산학협력단 Synthesis of 5-aminolevulinic acid trimer using citric acid for photodynamic therapy
CN102179010B (en) * 2011-05-27 2013-01-09 吉林大学 Photodynamic direct radiation therapy device for cerebral gliomas
WO2013111719A1 (en) * 2012-01-26 2013-08-01 Ｓｂｉファーマ株式会社 Photodynamic diagnostic agent and photobleaching inhibitor
US20140067024A1 (en) 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
GB201306369D0 (en) 2013-04-09 2013-05-22 Photocure As Irradiation device
KR20150004092A (en) * 2013-07-02 2015-01-12 제너럴바이오(주) Antioxidizing liquid composition including kalanchoe Gastonis-Bonnieri Extract for photodynamic therapy post treatment
CN105899201A (en) * 2013-12-20 2016-08-24 盖尔德马研究及发展公司 Pulse photodynamic treatment of photodamaged skin
PL229756B1 (en) 2014-11-12 2018-08-31 Tarchominskie Zaklady Farmaceutyczne Polfa Spólka Akcyjna Cream for use in diagnostics and therapy, using the photodynamic method
CN109939361B (en) * 2014-11-19 2021-04-06 夏普株式会社 photodynamic therapy device
WO2017066270A1 (en) 2015-10-15 2017-04-20 Dusa Pharmaceuticals, Inc. Adjustable illuminator for photodynamic therapy and diagnosis
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
EP3389716B1 (en) 2015-12-17 2022-03-23 Photocure ASA Method of photodynamic therapy (pdt) for bladder cancer
US10632324B2 (en) 2017-04-27 2020-04-28 9127-4910 Quebec Inc. Method for the treatment of skin tissues
US20200261580A1 (en) * 2017-07-17 2020-08-20 Andrea Willey Photodynamic Therapy Method for Skin Disorders
US10357567B1 (en) 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
WO2020038583A1 (en) 2018-08-23 2020-02-27 Biofrontera Bioscience Gmbh Photodynamic therapy comprising two light exposures at different wavelengths
US20220193124A1 (en) 2019-04-26 2022-06-23 Neopharma Japan Co., Ltd. Therapeutic Agent for Flavivirus Infection
AU2020303417B2 (en) * 2019-06-25 2025-08-28 Sun Pharmaceutical Industries, Inc. Methods for reducing pain during photodynamic therapy of actinic keratosis
JPWO2022014654A1 (en) * 2020-07-15 2022-01-20
CN113620828B (en) * 2021-08-17 2025-04-01 湖南复瑞生物医药技术有限责任公司 A 5-aminolevulinic acid ester, use and pesticide composition
KR102953140B1 (en) * 2023-08-07 2026-04-16 주식회사 아스트로젠 5-Aminolevulinic Acid Derivative and Pharmaceutical Composition Comprising the Same
WO2026158624A1 (en) * 2025-01-26 2026-07-30 Jiangsu Yahong Meditech Co., Ltd. Semi-solid pharmaceutical compositions containing stearic acid and palmitic acid

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028412A1 (en) * 1995-03-10 1996-09-19 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
WO1998030242A2 (en) * 1997-01-10 1998-07-16 Photocure As Photochemotherapeutic compositions
WO2002010120A1 (en) * 2000-07-27 2002-02-07 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
WO2003077911A1 (en) * 2002-03-15 2003-09-25 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20040048842A1 (en) * 2002-09-10 2004-03-11 Mcmillan Kathleen Method of treating skin disorders
WO2005092838A1 (en) * 2004-03-26 2005-10-06 Photocure Asa Acid addition salts of 5-aminolevulinic acid or its derivatives
WO2006051269A1 (en) * 2004-11-10 2006-05-18 Photocure Asa Treatment of acne using derivatives of 5-aminolevulinic acid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955490A (en) 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US5422093A (en) * 1989-07-28 1995-06-06 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5234940A (en) * 1989-07-28 1993-08-10 Queen's University Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
US5079262A (en) * 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
AUPQ044499A0 (en) 1999-05-19 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Control of wool growth
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
CA2422865C (en) 2000-08-16 2012-10-16 The General Hospital Corporation D/B/A Massachusetts General Hospital Aminolevulinic acid photodynamic therapy for treating sebaceous gland disorders
WO2003086460A2 (en) 2002-04-05 2003-10-23 Candela Corporation High fluence rate activation of photosensitizers for dermatological applications
WO2004034889A2 (en) * 2002-10-18 2004-04-29 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization
US20050209331A1 (en) 2004-03-22 2005-09-22 Syneron Medical Ltd. Method of treatment of skin
US20050209330A1 (en) * 2004-03-22 2005-09-22 Syneron Medical Ltd. Method of treatment of skin
GB0609809D0 (en) * 2006-05-17 2006-06-28 Photocure Asa Product

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028412A1 (en) * 1995-03-10 1996-09-19 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
WO1998030242A2 (en) * 1997-01-10 1998-07-16 Photocure As Photochemotherapeutic compositions
WO2002010120A1 (en) * 2000-07-27 2002-02-07 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
WO2003077911A1 (en) * 2002-03-15 2003-09-25 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20040048842A1 (en) * 2002-09-10 2004-03-11 Mcmillan Kathleen Method of treating skin disorders
WO2005092838A1 (en) * 2004-03-26 2005-10-06 Photocure Asa Acid addition salts of 5-aminolevulinic acid or its derivatives
WO2006051269A1 (en) * 2004-11-10 2006-05-18 Photocure Asa Treatment of acne using derivatives of 5-aminolevulinic acid

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CASAS, A. ET AL: "Photosensitization and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy", BRITISH JOURNAL OF CANCER , 85(2), 279-284 CODEN: BJCAAI; ISSN: 0007-0920, 2001, XP002485548 *
HÖRFELT C ET AL: "Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study.", THE BRITISH JOURNAL OF DERMATOLOGY SEP 2006, vol. 155, no. 3, September 2006 (2006-09-01), pages 608 - 613, XP002485547, ISSN: 0007-0963 *
ITOH Y ET AL: "PHOTODYNAMIC THERAPY FOR ACNE VULGARIS WITH TOPICAL 5-AMINOLEVULINIC ACID", ARCHIVES OF DERMATOLOGY, XX, XX, vol. 136, no. 9, 1 September 2000 (2000-09-01), pages 1093 - 1095, XP008038787, ISSN: 0003-987X *
JUZENIENE ASTA ET AL: "Topical application of 5-aminolevulinic acid and its methylester, hexylester and octylester derivatives: considerations for dosimetry in mouse skin model.", PHOTOCHEMISTRY AND PHOTOBIOLOGY SEP 2002, vol. 76, no. 3, September 2002 (2002-09-01), pages 329 - 334, XP002485544, ISSN: 0031-8655 *
MOAN JOHAN ET AL: "Influence of light exposure on the kinetics of protoporphyrin IX formation in normal skin of hairless mice after application of 5-aminolevulinic acid methyl ester.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY NOV 2005, vol. 125, no. 5, November 2005 (2005-11-01), pages 1039 - 1044, XP002485543, ISSN: 0022-202X *
POLLOCK B ET AL: "Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action.", THE BRITISH JOURNAL OF DERMATOLOGY SEP 2004, vol. 151, no. 3, September 2004 (2004-09-01), pages 616 - 622, XP001222029, ISSN: 0007-0963 *
SHARFAEI SORAYA ET AL: "Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumours in mice.", ARCHIVES OF DERMATOLOGICAL RESEARCH JUL 2002, vol. 294, no. 5, July 2002 (2002-07-01), pages 237 - 242, XP002485542, ISSN: 0340-3696 *
TARSTEDT MIKAEL ET AL: "A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp.", ACTA DERMATO-VENEREOLOGICA 2005, vol. 85, no. 5, 2005, pages 424 - 428, XP008093469, ISSN: 0001-5555 *
WIEGELL, STINE REGIN ET AL: "Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin", ARCHIVES OF DERMATOLOGY , 139(9), 1173-1177 CODEN: ARDEAC; ISSN: 0003-987X, 2003, XP008093462 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2615870C2 (en) * 2011-12-19 2017-04-11 ФотоКьюэр АСА Emitter

Also Published As

Publication number Publication date
US8759396B2 (en) 2014-06-24
CA2675334C (en) 2014-02-25
EP2120921A2 (en) 2009-11-25
EP2754439A3 (en) 2014-10-01
CN101631541A (en) 2010-01-20
GB0700580D0 (en) 2007-02-21
WO2008084241A2 (en) 2008-07-17
CN104069493A (en) 2014-10-01
KR20090118925A (en) 2009-11-18
CN104524576A (en) 2015-04-22
JP2014094963A (en) 2014-05-22
EP2754439A2 (en) 2014-07-16
PT2120921E (en) 2015-09-30
JP5814508B2 (en) 2015-11-17
US10543272B2 (en) 2020-01-28
US20100137439A1 (en) 2010-06-03
US20150150972A1 (en) 2015-06-04
US20130090592A1 (en) 2013-04-11
JP2010515714A (en) 2010-05-13
ES2546381T3 (en) 2015-09-23
ES2900528T3 (en) 2022-03-17
JP5827702B2 (en) 2015-12-02
CA2675334A1 (en) 2008-07-17
EP2120921B1 (en) 2015-06-17
DK2120921T3 (en) 2015-08-24
CA2784250C (en) 2016-03-15
SI2120921T1 (en) 2015-10-30
CA2784250A1 (en) 2008-07-17
US20160030565A1 (en) 2016-02-04
PL2120921T3 (en) 2015-12-31
EP2754439B1 (en) 2021-10-13
EP2659888A1 (en) 2013-11-06
KR20140076641A (en) 2014-06-20

Similar Documents

Publication Publication Date Title
US8759396B2 (en) Use of aminolevulinic acid and derivatives thereof
JP6933685B2 (en) Pulsed photodynamic treatment of light-damaged skin
US20100211137A1 (en) Acne therapeutic agent and sebum secernent inhibitor which comprise indole-3-alkylcarbo xylicacid, and kits for photodynamic therapy containing the same
Stritt et al. Photodynamic therapy in the treatment of actinic keratosis
ES2778031T3 (en) Method for treating acne
Torezan et al. Photodynamic therapy in dermatology: basic principles
CA2577441A1 (en) Improved photosensitizer formulations and their use
KR101308507B1 (en) Acne therapeutics and sebum secernent inhibitor which comprise tryptophan, and kits for photodynamic therapy containing the same
RU2674025C1 (en) Drug based on porphyrinic photosensitizer of coproporphyrin for treatment of skin cancer by photodynamic therapy method
Mikolajewska Asta Juzeniene
Echevarría et al. Red-diode laser photodynamic therapy of basal cell cancer using photosensitizer Radachlorin: preliminary results
Dickson et al. Photodynamic therapy using

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880002124.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701770

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008701770

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2675334

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009545231

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097016703

Country of ref document: KR

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 12523048

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020147014684

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020157033696

Country of ref document: KR